Use of camrelizumab in treatment of nasopharyngeal carcinoma
https://doi.org/10.17650/2222-1468-2024-14-4-51-54
Abstract
Nasopharyngeal carcinoma is a rare pathology. It develops in the nasopharyngeal mucosa and is characterized by aggressive (recurrent and metastatic) progression. Due to complicated location, this disease is often diagnosed at late stages and requires systemic therapy. Due to the rareness of nasopharyngeal carcinoma, until recently there were no studies on modern drug therapy of this pathology with high evidence level.
Aim. To describe the capabilities and mechanism of action of camrelizumab in nasopharyngeal carcinoma. The results of studies investigating the mechanism of action of camrelizumab were analyzed. The effectiveness of this drug in progression of nasopharyngeal cancer with previous chemotherapy and in combination with chemotherapy as the 1st line treatment of recurrent and / or metastatic process was evaluated. Based on the phase II trial results, the use of camrelizumab in patients with disease progression during standard chemotherapy allows to achieve progression-free survival of 8.5 months. Data obtained in the phase III trial demonstrated clinical benefit of adding this drug to standard chemotherapy in the 1st line therapy of recurrent and / or metastatic nasopharyngeal carcinoma: median progressionfree survival significantly increased from 6.9 to 9.7 months.
Therefore, camrelizumab is a modern highly effective immunotherapeutic drug designed to treat patients with nasopharyngeal carcinoma.
Keywords
nasopharyngeal cancer,
nasopharyngeal carcinoma,
squamous cell carcinoma,
camrelizumab,
immunotherapy
Supporting agencies: The article was prepared with the sponsorship of the Petrovax Pharm.
About the Authors
Yu. V. Alymov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
Yuri Vladimirovich Alymov
24 Kashirskoe Shosse, Moscow 115522
A. M. Mudunov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow Region 143081
I. S. Romanov
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115522
B. G. Pkheshkhova
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
111 1st Uspenskoe Shosse, Lapino, Moscow Region 143081
References
1. Han Y., Liu D., Li L. PD-1/PD-L1 pathway: current researches in cancer Am J Cancer Res 2020;10(3):727.
2. Wong K.C., Hui E.P. The role of PD-1 inhibitors in the treatment of nasopharyngeal carcinoma. Cancer Treat Rev 2018;67:88–98. DOI: 10.1016/j.oraloncology.2020.104640
3. Eagle R.A., Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev Immunol 2007;7(9):737–44. DOI: 10.1038/nri2144
4. Xu Y., Liu Y, Ge Y. et al. Drug resistance mechanism and reversal strategy in lung cancer immunotherapy. Front Pharmacol 2023;14:1230824. DOI: 10.3389/fphar.2023.1230824
5. Raulet D.H., Guerra N. Oncogenic stress sensed by the immune system: role of natural killer cell receptors. Nat Rev Immunol 2009;9(8):568–80. DOI: 10.1038/nri2604
6. Lanier L.L. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol 2008;9(5):495–502. DOI: 10.1038/ni1581
7. Groh V., Wu J., Yee C., Spies T. Tumor-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002;419(6908):734–8. DOI: 10.1038/nature01112
8. Lee A.W., Ma B.B., Ng W.T., Chan A.T. Management of nasopharyngeal carcinoma: current practice and future perspective. J Clin Oncol 2015;33(29):3356–64. DOI: 10.1200/JCO.2015.60.9347
Review
For citations:
Alymov Yu.V., Mudunov A.M., Romanov I.S., Pkheshkhova B.G. Use of camrelizumab in treatment of nasopharyngeal carcinoma. Head and Neck Tumors (HNT). 2024;14(4):51-54. (In Russ.) https://doi.org/10.17650/2222-1468-2024-14-4-51-54
Views:
106
Email this article 